Trial Profile
Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subjects aged ≥18 and ≤60 years and elderly subjects ≥61 years of age.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jun 2011
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine liposomal (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections
- Focus Pharmacodynamics
- Acronyms Invivac
- Sponsors Solvay Pharmaceuticals B.V.
- 18 May 2011 New trial record
- 18 May 2011 New trial record